Breath Therapeutics Holding BV
About Breath Therapeutics Holding BVBreath Therapeutics is specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases. For its clinical development, the company is using proprietary drug formulations optimized for inhaled administration with exclusively licenced, high performance nebulizers. Breath Therapeutics is focussing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy control. The clinical development program is addressing the treatment of Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. PARI Pharma, a leading nebulizer company, is strategic partner and technology licensee for the BOS development program. Breath Therapeutics is based in Munich and Frankfurt, Germany.
CEO: Jens Stegemann
CFO: Anne Burger
CSO: Gerhard Boerner
COO: Oliver Denk
9 articles with Breath Therapeutics Holding BV
Breath Therapeutics, a Zambon company, a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need, today announced presentations at three upcoming scientific conferences.
Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, announces the acquisition of Breath Therapeutics and its subsidiaries for € 140 million
Italian pharma company purchases Breath Therapeutics for up to €500 million, with €140 million up front
Gimv and other shareholders sell biopharmaceutical company Breath Therapeutics to Zambon after a fast development
Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics.
In five years it is estimated that about 25,000 people in the United States will develop bronchiolitis obliterans syndrome (BOS), which results in respiratory failure and death. But a late-stage treatment under development by Breath Therapeutics could be a possible remedy for this rare and dread ...
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS)
Breath Therapeutics, a private company developing advanced inhaled therapeutics in severe pulmonary orphan diseases, announced presentations at three upcoming scientific conferences.
PARI Pharma Development Featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) Is Licensed To Breath Therapeutics Holding BV
Breath Therapeutics Holding BV Spins Out of PARI Pharma With $46 Million and a Ready-to-Go Phase III Drug/Device Combo